Delivering Personalised Health and Care

Through this theme, we will work to improve self-care by patients, improve access to care in the community, and allow its integration in complex chronic conditions with a personalised approach.

We will provide NHS practitioners and patients with innovations in personalised medicine, medical devices and diagnostic tools that genuinely add value but not cost.

Research will focus on individual variability in drug response, both safety and efficacy with a view to evaluating the mechanisms, and identifying strategies to personalise healthcare in order to optimise drug efficacy and minimise toxicity.

The theme will also have continuous activity to evaluate and optimise the effectiveness of assistive technologies which have the capacity to improve outcomes for patients and to help deliver more efficient healthcare across the wider healthcare system as piloted in the TSB-funded DALLAS programme and specifically the Liverpool-based “More Independence” (Mi) project.

The Theme is currently supporting the design and development of the evaluation of the "Baby Box" initiative (NHS Halton CCG)

If you would like to find out more about our work in the area, please contact the Theme Leader, Professor Munir Pirmohamed via munirp@liverpool.ac.uk

Publications

Al‐Naher A, Wright D, Devonald MA, Pirmohamed M. Renal function monitoring in heart failure–what is the optimal frequency? A narrative review. British journal of clinical pharmacology. 2018 Jan;84(1):5-17. 
DOI: 10.1111/bcp.13434

Collins BJ, Cuddy K, Martin AP. Assessing the effectiveness and cost-effectiveness of drug intervention programs: UK case study. Journal of addictive diseases. 2017 Jan 2;36(1):5-13.
DOI: 10.1080/10550887.2016.1182299

Downing J., Gleeson H., Clayton PE., Davis JRE., Dimitri P., Wales J., Young B., Callery P. Communication with young people in paediatric and adult endocrine consultations: an intervention development and feasibility study. BMC Endocr Disord. 2017 Jun 15;17(1):33. 
DOI: 10.1186/s12902-017-0182-6

Gibson A, Ogese M, Pirmohamed M. Genetic and nongenetic factors that may predispose individuals to allergic drug reactions. Current opinion in allergy and clinical immunology. 2018 Aug 1;18(4):325-32.
DOI: 10.1097/ACI.0000000000000459

Martin AP, Downing J, Cochrane M, Collins B, Francis B, Haycox A, Alfirevic A, Pirmohamed M. Trastuzumab uptake in HER2-positive breast cancer patients: A systematic review and meta-analysis of observational studies. Critical reviews in oncology/hematology. 2018 Aug 3.
DOI: 10.1016/j.critrevonc.2018.07.012

Martin A, Downing J, Maden M, Fleeman N, Alfirevic A, Haycox A, Pirmohamed M. An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. Pharmacogenomics. 2017 Nov;18(16):1541-50.
DOI: 10.2217/pgs-2017-0076

Pennington B, Collins B, Leigh S, Martin AP, Owen L, Fischer A, Sumnall H, Bates G. The cost-effectiveness of seven behavioural interventions to prevent drug misuse in vulnerable populations. International Journal of Drug Policy. 2018 Jul 1;57:42-50.
DOI: 10.1016/j.drugpo.2018.03.028

Phillips EJ, Sukasem C, Whirl‐Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George Jr AL, Mushiroda T. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clinical Pharmacology & Therapeutics. 2018 Apr;103(4):574-81.
DOI: 10.1002/cpt.1004

Pirmohamed M. Nucleic acid based therapies: developing frontier for precision medicine. BMJ. 2018 Jan 23; 360(k223)  
DOI: 10.1136/bmj.k223  

Rao C, Smith FM, Martin AP, Dhadda AS, Stewart A, Gollins S, Collins B, Athanasiou T, Myint AS. A cost-effectiveness analysis of contact x-ray brachytherapy for the treatment of patients with rectal cancer following a partial response to chemoradiotherapy. Clinical Oncology. 2018 Mar 1;30(3):166-77. 
DOI: 10.1016/j.clon.2017.11.015 

Rao C, Sun Myint A, Athanasiou T, Faiz O, Martin AP, Collins B, Smith FM. Avoiding radical surgery in elderly patients with rectal cancer is cost-effective. Diseases of the Colon & Rectum. 2017 Jan 1;60(1):30-42.
DOI: 10.1097/DCR.0000000000000708